NWT-02, a fixed combination of lutein, zeaxanthin and docosahexaenoic acid in egg yolk and reduction of the loss of vision : evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006

Visa fullständig post



Permalänk

http://hdl.handle.net/10138/298809

Citation

EFSA Panel Dietetic Prod Nutr 2018 , ' NWT-02, a fixed combination of lutein, zeaxanthin and docosahexaenoic acid in egg yolk and reduction of the loss of vision : evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 ' , EFSA Journal , vol. 16 , no. 1 , 5139 . https://doi.org/10.2903/j.efsa.2018.5139

Titel: NWT-02, a fixed combination of lutein, zeaxanthin and docosahexaenoic acid in egg yolk and reduction of the loss of vision : evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006
Författare: EFSA Panel Dietetic Prod Nutr
Datum: 2018-01
Språk: eng
Sidantal: 12
Tillhör serie: EFSA Journal
ISSN: 1831-4732
Permanenta länken (URI): http://hdl.handle.net/10138/298809
Abstrakt: Following an application from Newtricious R&D B.V., submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of the Netherlands, the EFSA Panelon Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to NWT-02 and a reduction of the loss of vision. The food proposed by the applicant as the subject of the health claim is NWT-02. NWT-02 is standardised by its content in lutein (>= 1.10 mg), zeaxanthin (>= 0.20 mg) and docosahexaenoic acid (DHA) (>= 170 mg). The Panel considers that the food/constituent that is the subject of the health claim, NWT-02, a fixed combination of lutein, zeaxanthin and docosahexaenoic acid in egg yolk, is sufficiently characterised. The claimed effect proposed by the applicant is 'reduces loss of vision'. The target population proposed by the applicant is 'healthy adults over 50 years of age'. The Panel considers that a reduction of the loss of vision is a beneficial physiological effect. The applicant provided two human intervention studies for the scientific substantiation of the claim. The Panel considers that the only study from which conclusions can be drawn for the scientific substantiation of the claim did not show an effect of NWT-02 on vision. The Panel concludes that a cause and effect relationship has not been established between the consumption of NWT-02, a fixed combination of lutein, zeaxanthin and docosahexaenoic acid in egg yolk, and a reduction of the loss of vision. (c) 2018 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf of European Food Safety Authority.
Subject: NWT-02
vision
vision acuity
health claim
BUTTERMILK
416 Food Science
Licens:


Filer under denna titel

Totalt antal nerladdningar: Laddar...

Filer Storlek Format Granska
Panel_et_al_2018_EFSA_Journal_2.pdf 733.2Kb PDF Granska/Öppna

Detta dokument registreras i samling:

Visa fullständig post